Navigation Links
Karmanos Cancer Institute Immunology Researcher Obtains Nearly $1 Million National Institutes of Health Grant
Date:10/20/2009

DETROIT, Oct. 20 /PRNewswire-USNewswire/ -- Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment. Dr. Poojary's grant brings the total number of federal stimulus grant dollars received by Karmanos researchers to approximately $8 million this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO )

Among the more than 20,000 applications the National Institutes of Health received for the NIH Challenge Grants, Dr. Poojary's application ranked within the top 1 percent. He received a grant for $999,094. The NIH has allocated $200 million for the challenge grants for fiscal years 2009 and 2010. They are part of the American Recovery and Reinvestment Act of 2009 passed in February of this year.

Dr. Poojary's research is titled, "Role of TIEG1 in Foxp3+Treg development and tumor progression," and explores tumor pathways that cause effector T cells, those that help maintain a healthy immune system, to be converted to regulator T cells, which allow the growth of cancerous tumor cells.

Researchers have already created vaccines that are effective in controlling regulator T cells in the lab environment, but so far immunotherapy vaccines have not been successful when used on humans.

"Immunotherapy for cancer has not been successful because tumors exploit the immune system," Dr. Poojary said. "We must now build on immunotherapy's great cancer treatment potential by learning how we can make it more effective."

Dr. Poojary's research strives to understand on a molecular level how immune suppressor cells can be controlled so that tumor cells do not proliferate. He believes this research will provide him and his colleagues significant new insight to overcome the limitations of current immunotherapy strategies.

"We want to develop inhibitors for regulator T cells to use along with tumor vaccines, and our goal is to block the development of tumor-promoting regulator T cells in the tumor microenvironment," he said. "People have tried to deplete regulator T cells from the body using antibodies, but such an approach is associated with the risk of triggering autoimmunity in patients."

The nearly $1 million NIH grant will allow Dr. Poojary and his staff to invest the grant monies in what they need to conduct work more quickly and efficiently. As part of the grant, Dr. Poojary will hire four people to assist him. Without the grant, he says this research would have been very difficult.

"If we can understand the pathway of T cells, we will be very close to determining the inhibitors for what converts good cells into tumor-promoting bad cells," he said. "This is the hard step, but I am very confident that I'll achieve my goals with the project."

Dr. Poojary says it will be significant when doctors can control the conversion of normal T cells into abnormal cells that allow tumors to grow. "With this knowledge, we would be very close to having the immunological tools to more effectively treat aggressive cancers, such as locally-advanced and metastatic breast cancer, prostate cancer and brain cancer," according to Dr. Poojary. He said he is fascinated by the intricacies of the immune system and how systems differ from patient to patient.

"I'm interested in knowing how the immune system works," he said. "Immunotherapy is the future for cancer treatment and it can be developed for any disease. Immunotherapy is much safer, but we have to improve the efficiency of tumor vaccines so that you get more specific and longer-lasting effects."

Dr. Poojary has been studying immunology since 1998 when he began his doctorate studies at the National Center for Cell Science in Pune, India. After receiving his Ph.D., he served as a postdoctoral fellow and later a research scientist in the Division of Cell Biology at LaJolla Institute for Allergy and Immunology in San Diego, Calif. He has been with the Karmanos Cancer Institute since March 2009.

About the Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to karmanos.org.

SOURCE Barbara Ann Karmanos Cancer Institute


'/>"/>
SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Susan G. Komen for the Cure, Karmanos Cancer Institute, Community Leaders, Breast Cancer Survivors and Activists to Gather at Forum and Call for Action on Breast Cancer
2. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
3. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
4. Danialle Karmanos Work It Out Launches Dynamic Blog
5. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
6. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
7. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
8. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
9. Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services
10. J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: